BibTex RIS Kaynak Göster

Multiple sclerosis: relationships between cytokines, MRI lesion burden, visual evoked potentials and disability scores

Yıl 2010, Cilt: 7 Sayı: 2, 167 - 173, 01.06.2010

Öz

Kaynakça

  • Beer S, Rosler KM, Hess CW. Diagnostic value of para- clinical tests in multiple sclerosis: relative sensitivities and specifities for reclassification according to the Poser Committee criteria. J Neurol Neurosurg Psychiatry 1995; 59:152-9.
  • Bednarik J, Kadanka Z. Multimodal sensory and motor evoked potentials in a two-year follow-up study of MS pa- tients with relapsing course. Acta Neurol Scand 1992; 86:15-8.
  • Kurtzke J. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
  • Iragui VJ, Wiederholt WC, Romine JS. Serial recordings of multimodality evoked potentials in multiple sclerosis. Can J Neurol Sci 1986;13: 320-6.
  • Anderson DC, Slater GE, Sherman R, Ettinger MG. Evoked potentials to test a treatment of chronic multiple sclero- sis. Arch Neurol 1987;44:1232-6.
  • Isaac C, Li DK, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988;38: 1511-5.
  • Sater RA, Rostami AM, Galetta S, Farber RE, Bird SJ. Serial evoked potential studies and MRI imaging in chronic pro- gressive multiple sclerosis. J Neurol Sci 1999;171: 79–83.
  • Eikelenboom MJ, Killestein J, Uitdehaag BMJ, CH Polman CH. Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis. Multiple Sclerosis 2005;11:520-3.
  • Charlton B, Lafferty KJ. The Th1/Th2 balance in autoim- munity. Curr Opin Immunol 1995;7:793-8.
  • Uhlenbrock D, Seidel D, Gehlen W, et al. MR imaging in multiple sclerosis: comparison with clinical, CSF and vi- sual evoked potential findings. AJNR 1988;9:59-67.
  • Gareau PJ, Gati JS, Menon RS, et al. Reduced visual evoked responses in multiple sclerosis patients with optic neuritis: Comparison of functional magnetic resonance imaging and visual evoked potentials. Multiple Sclerosis 1999;5;161-4.
  • McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for MS: Guidelines from the interna- tional Panel on the diagnostic of MS. Ann Neurology 2001; 50: 121-7.
  • Skurkovich S,Boiko A, Beliaeva A, et al. Randomized study of antibodies to IFN-g and TNF-a in secondary progressive multiple sclerosis. Multiple Sclerosis 2001;7:277-84.
  • Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple scle- rosis: from bench to bedside. Pharmacology Theraputics 2005;106:163-77.
  • Liu J, Marino MW, Wong G, et al. TNF is a potent anti- inflammatory cytokine in autoimmune-mediated demy- elination. Nat Med 1998;4:78– 83.
  • Hellings N, Raus J, Stinissen P. Insights into the immu- nopathogenesis of multiple sclerosis. Immunol Res 2002; 25:27–51.
  • Hautecoeour P, Forzy G, Gallois P, Demirbilek V, Feagas O. Variations of Il-2, IL-6 and TNF- plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol Belg 1997;97:240-3.
  • Anlar O, Kıslı M, Tombul T, Ozbek H. Visual evoked poten- tials in multiple sclerosis before and after two years of interferon therapy. Int J Neuroscience 2003;113: 483-9.
  • Khoury SJ, Weiner HL. Multiple sclerosis. What have we learned from magnetic resonance imaging studies? Arch Intern Med 1998;158: 565-73.
  • Comi G, Filippi M, Rovaris M, Leocani L, Medaglini S, Locatelli T. Clinical, neurophysiological, and magnetic resonance imaging correlations in multiple sclerosis. J Neurol Neurosurg Psychiatry Suppl 1, 1998;64:21–5.
  • Paty DW, McFarland H. Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pa- thology and to monitor definitive clinical trials. J Neurol Neurosurg Psychiatry, Suppl 1, 1998; 64: 47–51.
  • Fillipi M, Mastronardo G, Bastianello S, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow up study. Neurology 1995; 45: 255-260.
  • Truyen L, van Waerberghe JH, van Walderveen MA, et al. Accumulation of hypotense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in mul- tiple sclerosis. Neurology 1996;47:1469-76.
  • Miller DH, Grosmann RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121:3-24.
  • O’Conner P, Marchetti P, Lee L, Perera M. Evoked poten- tial abnormality scores are useful measure of disease bur- den in relapsing-remitting multiple sclerosis. Ann Neurol 1998;44: 404-7.
  • Fuhr P, Kappos L. Evoked potentials for evaluation of mul- tiple sclerosis. Clin Neurophysio, 2001;112: 2185–9.
  • Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Visual and motor evoked potentials in the course of mul- tiple sclerosis. Brain 2001;124: 2162-8.

Multiple sclerosis: relationships between cytokines, MRI lesion burden, visual evoked potentials and disability scores

Yıl 2010, Cilt: 7 Sayı: 2, 167 - 173, 01.06.2010

Öz

-

Kaynakça

  • Beer S, Rosler KM, Hess CW. Diagnostic value of para- clinical tests in multiple sclerosis: relative sensitivities and specifities for reclassification according to the Poser Committee criteria. J Neurol Neurosurg Psychiatry 1995; 59:152-9.
  • Bednarik J, Kadanka Z. Multimodal sensory and motor evoked potentials in a two-year follow-up study of MS pa- tients with relapsing course. Acta Neurol Scand 1992; 86:15-8.
  • Kurtzke J. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
  • Iragui VJ, Wiederholt WC, Romine JS. Serial recordings of multimodality evoked potentials in multiple sclerosis. Can J Neurol Sci 1986;13: 320-6.
  • Anderson DC, Slater GE, Sherman R, Ettinger MG. Evoked potentials to test a treatment of chronic multiple sclero- sis. Arch Neurol 1987;44:1232-6.
  • Isaac C, Li DK, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988;38: 1511-5.
  • Sater RA, Rostami AM, Galetta S, Farber RE, Bird SJ. Serial evoked potential studies and MRI imaging in chronic pro- gressive multiple sclerosis. J Neurol Sci 1999;171: 79–83.
  • Eikelenboom MJ, Killestein J, Uitdehaag BMJ, CH Polman CH. Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis. Multiple Sclerosis 2005;11:520-3.
  • Charlton B, Lafferty KJ. The Th1/Th2 balance in autoim- munity. Curr Opin Immunol 1995;7:793-8.
  • Uhlenbrock D, Seidel D, Gehlen W, et al. MR imaging in multiple sclerosis: comparison with clinical, CSF and vi- sual evoked potential findings. AJNR 1988;9:59-67.
  • Gareau PJ, Gati JS, Menon RS, et al. Reduced visual evoked responses in multiple sclerosis patients with optic neuritis: Comparison of functional magnetic resonance imaging and visual evoked potentials. Multiple Sclerosis 1999;5;161-4.
  • McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for MS: Guidelines from the interna- tional Panel on the diagnostic of MS. Ann Neurology 2001; 50: 121-7.
  • Skurkovich S,Boiko A, Beliaeva A, et al. Randomized study of antibodies to IFN-g and TNF-a in secondary progressive multiple sclerosis. Multiple Sclerosis 2001;7:277-84.
  • Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple scle- rosis: from bench to bedside. Pharmacology Theraputics 2005;106:163-77.
  • Liu J, Marino MW, Wong G, et al. TNF is a potent anti- inflammatory cytokine in autoimmune-mediated demy- elination. Nat Med 1998;4:78– 83.
  • Hellings N, Raus J, Stinissen P. Insights into the immu- nopathogenesis of multiple sclerosis. Immunol Res 2002; 25:27–51.
  • Hautecoeour P, Forzy G, Gallois P, Demirbilek V, Feagas O. Variations of Il-2, IL-6 and TNF- plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol Belg 1997;97:240-3.
  • Anlar O, Kıslı M, Tombul T, Ozbek H. Visual evoked poten- tials in multiple sclerosis before and after two years of interferon therapy. Int J Neuroscience 2003;113: 483-9.
  • Khoury SJ, Weiner HL. Multiple sclerosis. What have we learned from magnetic resonance imaging studies? Arch Intern Med 1998;158: 565-73.
  • Comi G, Filippi M, Rovaris M, Leocani L, Medaglini S, Locatelli T. Clinical, neurophysiological, and magnetic resonance imaging correlations in multiple sclerosis. J Neurol Neurosurg Psychiatry Suppl 1, 1998;64:21–5.
  • Paty DW, McFarland H. Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pa- thology and to monitor definitive clinical trials. J Neurol Neurosurg Psychiatry, Suppl 1, 1998; 64: 47–51.
  • Fillipi M, Mastronardo G, Bastianello S, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow up study. Neurology 1995; 45: 255-260.
  • Truyen L, van Waerberghe JH, van Walderveen MA, et al. Accumulation of hypotense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in mul- tiple sclerosis. Neurology 1996;47:1469-76.
  • Miller DH, Grosmann RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121:3-24.
  • O’Conner P, Marchetti P, Lee L, Perera M. Evoked poten- tial abnormality scores are useful measure of disease bur- den in relapsing-remitting multiple sclerosis. Ann Neurol 1998;44: 404-7.
  • Fuhr P, Kappos L. Evoked potentials for evaluation of mul- tiple sclerosis. Clin Neurophysio, 2001;112: 2185–9.
  • Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Visual and motor evoked potentials in the course of mul- tiple sclerosis. Brain 2001;124: 2162-8.
Toplam 27 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Makaleler
Yazarlar

Nebahat Taşdemir Bu kişi benim

Erdal Eren Karaca Bu kişi benim

Yavuz Yücel

Süber Dikici Bu kişi benim

Mehmet Serhan Taşdemir Bu kişi benim

Yayımlanma Tarihi 1 Haziran 2010
Yayımlandığı Sayı Yıl 2010 Cilt: 7 Sayı: 2

Kaynak Göster

APA Taşdemir, N., Karaca, E. E., Yücel, Y., Dikici, S., vd. (2010). Multiple sclerosis: relationships between cytokines, MRI lesion burden, visual evoked potentials and disability scores. European Journal of General Medicine, 7(2), 167-173.
AMA Taşdemir N, Karaca EE, Yücel Y, Dikici S, Taşdemir MS. Multiple sclerosis: relationships between cytokines, MRI lesion burden, visual evoked potentials and disability scores. European Journal of General Medicine. Haziran 2010;7(2):167-173.
Chicago Taşdemir, Nebahat, Erdal Eren Karaca, Yavuz Yücel, Süber Dikici, ve Mehmet Serhan Taşdemir. “Multiple Sclerosis: Relationships Between Cytokines, MRI Lesion Burden, Visual Evoked Potentials and Disability Scores”. European Journal of General Medicine 7, sy. 2 (Haziran 2010): 167-73.
EndNote Taşdemir N, Karaca EE, Yücel Y, Dikici S, Taşdemir MS (01 Haziran 2010) Multiple sclerosis: relationships between cytokines, MRI lesion burden, visual evoked potentials and disability scores. European Journal of General Medicine 7 2 167–173.
IEEE N. Taşdemir, E. E. Karaca, Y. Yücel, S. Dikici, ve M. S. Taşdemir, “Multiple sclerosis: relationships between cytokines, MRI lesion burden, visual evoked potentials and disability scores”, European Journal of General Medicine, c. 7, sy. 2, ss. 167–173, 2010.
ISNAD Taşdemir, Nebahat vd. “Multiple Sclerosis: Relationships Between Cytokines, MRI Lesion Burden, Visual Evoked Potentials and Disability Scores”. European Journal of General Medicine 7/2 (Haziran 2010), 167-173.
JAMA Taşdemir N, Karaca EE, Yücel Y, Dikici S, Taşdemir MS. Multiple sclerosis: relationships between cytokines, MRI lesion burden, visual evoked potentials and disability scores. European Journal of General Medicine. 2010;7:167–173.
MLA Taşdemir, Nebahat vd. “Multiple Sclerosis: Relationships Between Cytokines, MRI Lesion Burden, Visual Evoked Potentials and Disability Scores”. European Journal of General Medicine, c. 7, sy. 2, 2010, ss. 167-73.
Vancouver Taşdemir N, Karaca EE, Yücel Y, Dikici S, Taşdemir MS. Multiple sclerosis: relationships between cytokines, MRI lesion burden, visual evoked potentials and disability scores. European Journal of General Medicine. 2010;7(2):167-73.